StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Equities research analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $1.08 on Tuesday. The firm’s fifty day moving average price is $2.04. The company has a market cap of $4.84 million, a price-to-earnings ratio of -0.12 and a beta of 0.31. Oragenics has a 1 year low of $1.02 and a 1 year high of $7.74.

Oragenics (NYSE:OGEN) last issued its quarterly earnings results on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in shares of Oragenics by 388.9% in the first quarter. Renaissance Technologies LLC now owns 96,800 shares of the company’s stock valued at $33,000 after purchasing an additional 77,000 shares in the last quarter. State Street Corp lifted its holdings in shares of Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the company’s stock valued at $171,000 after purchasing an additional 37,338 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Oragenics by 591.6% in the second quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock valued at $45,000 after purchasing an additional 110,119 shares in the last quarter. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.